Milestone Pharmaceuticals Inc.
NASDAQ:MISTBiotechnology
-$0.00 today
- Market cap
- $57.32M
- Beta
- 0.96
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$0.52
Volume 2.23M
Average 1.99M
MIST Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Milestone Pharmaceuticals Inc.NASDAQ: MIST
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $56K rose 107.4% year over year, ahead of the +37.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 64.7% from the prior quarter. Over 3 fiscal years it compounded at +8.6% a year.
Context
- Depreciation & amortization amounted to 7.4% of revenue in FY2025.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +107.4% holds above the trailing-twelve-month pace of +37.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 114K USD
- Year-over-year change
- +8.6%
- 4-year CAGR
- +5.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 114K | +8.6% |
| FY2024 | 2024-12-31 | 105K | +14.1% |
| FY2023 | 2023-12-31 | 92K | +3.4% |
| FY2022 | 2022-12-31 | 89K | -4.3% |
| FY2021 | 2021-12-31 | 93K | — |
Depreciation & Amortization vs competitors
How MIST compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +37.5% is the 3rd highest of 8, against a peer median of -2.3%.
- Depreciation & amortization amounts to 8.0% of revenue for MIST, versus a peer median of 182.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | €5.09M EUR | +155.3% | -51.8% | 182.7% | |
| LTM Mar 2026 | $3.2M USD | -40.7% | +41.5% | — | |
| LTM Mar 2026 | CHF 2.61M CHF | +9.7% | -3.5% | — | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $1.14M USD | -2.3% | +2.2% | — |
| LTM Mar 2026 | $1.03M USD | +94.7% | +56.5% | 196.6% | |
| LTM Mar 2026 | $810K USD | -21.4% | +18.0% | 25.6% | |
| LTM Mar 2026 | $248K USD | -57.2% | -46.1% | — | |
| LTM Mar 2026 | $143K USD | +37.5% | +8.6% | 8.0% | |
| Peer median (excluding MIST) | — | -2.3% | +2.2% | 182.7% | |
Competitors are the stored peer set for MIST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 15M | 5M | 1M | 0 | 1.55M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 114K |
| Gross Profit | 15M | 5M | 1M | 0 | 1.43M |
| Gross Margin | 100.0% | 100.0% | 100.0% | — | 92.6% |
| Research & Development | 38.67M | 39.83M | 31.05M | 14.36M | 18.11M |
| Selling, General & Admin | 19.4M | 24.81M | 31.05M | 27.75M | 17.27M |
| Operating Expenses | 58.07M | 64.64M | 62.1M | 42.1M | 63.92M |
| Depreciation & Amortization | 93K | 89K | 92K | 105K | 114K |
| EBITDA | (42.76M) | (58.3M) | (57.04M) | (37.83M) | (59.45M) |
| EBITDA Margin | -285.1% | -1166.0% | -5703.9% | — | -3845.5% |
| Operating Income | (43.07M) | (59.64M) | (61.1M) | (42.1M) | (62.49M) |
| Operating Margin | -287.2% | -1192.8% | -6109.8% | — | -4041.7% |
| Interest Income | 220K | 1.25M | 3.97M | 4.16M | 2.92M |
| Interest Expense | 0 | 0 | 2.55M | (3.58M) | 3.84M |
| Other Income / Expenses | 220K | 1.25M | 1.41M | 583K | (918K) |
| Income Before Tax | (42.85M) | (58.39M) | (59.69M) | (41.52M) | (63.4M) |
| Pre-Tax Margin | -285.7% | -1167.8% | -5968.5% | — | -4101.1% |
| Income Tax Expense | 0 | 0 | 0 | 0 | (345K) |
| Net Income | (42.85M) | (58.39M) | (59.69M) | (41.52M) | (63.06M) |
| Net Margin | -285.7% | -1167.8% | -5968.5% | — | -4078.8% |
| EPS (Basic) | (1.02) | (1.35) | (1.39) | (0.67) | (0.75) |
| EPS (Diluted) | (1.02) | (1.35) | (1.39) | (0.67) | (0.75) |
| Weighted Avg Shares | 41.83M | 42.45M | 42.96M | 62.21M | 83.88M |
| Weighted Avg Shares (Diluted) | 41.83M | 42.45M | 42.96M | 62.21M | 83.88M |
Milestone Pharmaceuticals Inc.
NASDAQ:MIST
Intrinsic Alpha fair value
Locked
Current Price
$0.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.